Innate Pharma (EURONEXT:IPHA), (NASDAQ:IPHA) specializes in the development of innovative therapeutic antibodies that aim to improve the treatment of cancer. This French biotech company is focused on harnessing the immune system’s power to develop novel, first-in-class therapeutic antibodies for oncology. Innate Pharma's pipeline includes candidates in clinical and preclinical stages that target immune checkpoints and other receptors to stimulate the immune response against cancer. The company's projects are a mix of proprietary programs and collaborations with major pharmaceutical companies, aiming to address unmet medical needs in oncology. Innate Pharma's objective is to leverage its expertise in immunology and antibodies to bring new treatment options to cancer patients.